Akebia Therapeutics — Third Quarter 2026 Earnings Summary

Akebia Therapeutics reported third-quarter 2026 net product revenues of $14.8 million for Vafseo, driven by approximately 11,500 active patients, a 140% increase from the prior year. The company announced positive topline data from the VOCAL trial showing non-inferiority to erythropoiesis-stimulating agents and presented VOICE trial results demonstrating improved safety outcomes for patients treated with a three-times-weekly vadadustat regimen. Financial results for the quarter included total revenues of $36.9 million and a net loss of $14.4 million, while the company maintained a cash position of approximately $159.3 million. Additionally, Akebia dosed the first patient in a Phase 2 basket trial for ebribafusp alfa targeting rare kidney diseases, with initial data expected in 2027.